Eupraxia Pharmaceuticals Q2 EPS Beats Estimate
Eupraxia Pharmaceuticals reports Q2 EPS of $(0.23), beating the estimate of $(0.25)
Eupraxia Pharmaceuticals (TSX: EPRX ) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) by 8 percent.
This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.